You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,296,821

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,296,821

Title:	Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodies
Abstract:	New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin\'s lymphomas.
Inventor(s):	Grillo-Lopez; Antonio J. (Rancho Sante Fe, CA)
Assignee:	Biogen Inc. (Cambridge, MA)
Application Number:	13/524,896
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,296,821
Patent Claims:	1. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient a therapeutically effective amount of rituximab during a chemotherapeutic regimen, wherein the chemotherapeutic regimen consists of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the method comprises administering 375 mg/m.sup.2 of rituximab, and wherein the method provides a beneficial synergistic effect in the patient. 2. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m.sup.2 of C2B8 during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy). 3. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m.sup.2 of a chimeric anti-CD20 antibody during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the chimeric anti-CD20 antibody is produced from nucleic acid encoding a light chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain and kappa light-chain constant region sequences. 4. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient a therapeutically effective amount of rituximab during a chemotherapeutic regimen, wherein the chemotherapeutic regimen consists of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the method comprises administering 375 mg/m.sup.2 of rituximab once every 3 weeks for 8 doses, and wherein the method provides a beneficial synergistic effect in the patient. 5. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m.sup.2 of C2B8 once every 3 weeks for 8 doses during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy). 6. A method for treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising administering to a patient 375 mg/m.sup.2 of a chimeric anti-CD20 antibody once every 3 weeks for 8 doses during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the chimeric anti-CD20 antibody is produced from nucleic acid encoding a light chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain and kappa light-chain constant region sequences.

Details for Patent 9,296,821

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2018-08-11
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2018-08-11
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2018-08-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.